<div id="readability-page-1"><div><p>Kissei Pharmaceutical (TSE:4547) has just wrapped up FY 2026 with fourth quarter revenue of ¥24.8b and Basic EPS of ¥66.70, rounding out a year in which trailing twelve month revenue reached ¥97.4b and EPS came in at ¥331.53. Over the past few quarters the company has seen revenue move from ¥22.7b and EPS of ¥72.91 in Q4 FY 2025 to ¥24.8b and EPS of ¥66.70 in Q4 FY 2026, while trailing net profit over the last year totaled ¥13.8b as margins edged higher. With a 14.1% net margin and a current share price of ¥4,355, these results may prompt investors to focus closely on how sustainable the recent profitability profile really is.</p> <p>See our full analysis for Kissei Pharmaceutical.</p><p>With the headline numbers on the table, the next step is to see how this earnings picture lines up with the widely followed narratives around Kissei, and where the data may challenge some of those views.</p> <p>Curious how numbers become stories that shape markets? Explore Community Narratives</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0d6d03d8-4453-4781-a90d-fab9afa355f5/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTEy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0d6d03d8-4453-4781-a90d-fab9afa355f5/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTEy"/><figcaption>TSE:4547 Revenue &amp; Expenses Breakdown as at May 2026</figcaption></figure> <h2>14.1% margin and one off gain skew the headline</h2> <ul> <li>Kissei reported a 14.1% net margin over the last 12 months on ¥97,406 million of revenue and ¥13,779 million of net income, supported by a one off gain of ¥18,400 million that meaningfully lifts the profitability picture.</li> <li>What stands out for a bullish view is that earnings grew 15.2% over the past year and averaged about 12% per year over five years. However, part of the recent strength comes from that ¥18,400 million one off, which means investors who are optimistic on the business still need to separate underlying profit from this extra boost when they think about how repeatable the 14.1% margin really is.     <ul> <li>Bulls pointing to the 15.2% earnings growth and five year record can lean on the trailing margin improvement from 13.5% to 14.1%, but the large gain makes those percentages look stronger than the core business alone.</li> <li>At the same time, trailing twelve month EPS of ¥331.53 sits above the prior year level of ¥274.20, which supports a bullish story on progress, while also underlining why adjusting for the one off item is important for anyone focusing on earnings per share.</li> </ul> </li> </ul> <h2>P/E of 13.1x with DCF fair value above price</h2> <ul> <li>The stock trades on a trailing P/E of 13.1x, compared with 15.4x for the broader JP Pharmaceuticals industry and 12.6x for direct peers, while the DCF fair value of ¥5,953.51 sits above the current ¥4,355 share price and indicates a gap of about 26.8% to that modelled value.</li> <li>Analysts with a bullish tilt argue that the combination of earnings growth and this valuation gap supports upside potential. Yet the numbers also introduce some balance because the stock is cheaper than the wider industry but slightly richer than peers on P/E, and analyst targets around ¥5,316.67 point to a smaller upside than the DCF fair value suggests.     <ul> <li>The trailing P/E sitting below the 15.4x industry average aligns with the idea that the stock is not priced at a premium, while the 13.1x level versus 12.6x for peers hints that investors are already paying a bit more than for some similar companies despite the one off gain affecting earnings.</li> <li>Against that, a share price of ¥4,355 compared to the ¥5,953.51 DCF fair value and the ¥5,316.67 analyst target range supports the bullish argument that current pricing leaves room if earnings and cash flows track closer to those implied levels.</li> </ul> </li> </ul> <h2>Forecast growth slower than wider market</h2> <ul> <li>Consensus expects earnings to grow about 0.6% per year and revenue about 3.9% per year, both below the JP market forecasts of 10.3% earnings growth and 6.1% revenue growth, even though Kissei currently supports a 2.76% dividend yield on the ¥4,355 share price.</li> <li>For a more cautious, bearish leaning view, critics highlight that slower forecast growth versus the broader market and the impact of the ¥18,400 million one off gain on recent results can limit how much weight to put on the trailing 15.2% earnings growth. This means some investors may treat the current valuation and dividend as fair compensation for steadier, rather than fast, expansion.     <ul> <li>The gap between 0.6% forecast earnings growth and the market’s 10.3% figure challenges any idea that the recent double digit earnings growth rate automatically continues, especially when the last 12 months include the sizeable one off gain.</li> <li>At the same time, the 2.76% dividend yield gives holders an income stream, which bears may see as a support for total return even if the growth forecasts stay below the broader JP market.</li> </ul> </li> </ul> <h2>Next Steps</h2> <p>Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Kissei Pharmaceutical's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.</p> <p>If this mix of positives and concerns feels finely balanced, it is worth checking the numbers yourself and deciding where you stand. To see both sides clearly, take a look at the 4 key rewards and 1 important warning sign.</p> <h2>See What Else Is Out There</h2> <p>Kissei's recent results include a large one off gain, while forecast earnings and revenue growth remain well below the wider JP market.</p> <p>If you are concerned that slower growth and non recurring boosts may limit the long term appeal here, compare this profile with 11 high quality undervalued stocks to find stocks where pricing and fundamentals may align more closely with your expectations.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if Kissei Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

4547

<p>Kissei Pharmaceutical (TSE:4547) reported FY 2026 Q4 revenue of ¥24.8b and Basic EPS of ¥66.70, with trailing twelve month revenue at ¥97.4b and EPS at ¥331.53. A one-off gain of ¥18.4b boosted margins to 14.1%. Despite a 15.2% earnings growth, analysts caution about sustainability due to this gain. The stock trades at a trailing P/E of 13.1x, below the industry average, with a DCF fair value of ¥5,953.51 suggesting upside potential. However, forecast growth is slower than the broader market, raising concerns about future performance.</p>

Kissei Pharmaceutical (TSE:4547) One Off Gain Lifts Margin And Tests Bullish Earnings Narrative